IP Library Granted Patent US 9,404,927
Granted Patent B2
US 9,404,927 · App. 14/561,313 · Granted Aug 2, 2016

Systems and methods for diagnosing and treating cancer

Inventors: Timothy G. Whitsett (Phoenix, AZ); Nhan L. Tran (Phoenix, AZ)
Assignee: The Translational Genomics Research Institute
G01N33/57423A61K31/713A61K45/06C12N15/1138C12Q1/6886C12N2310/11C12N2310/14C12N2320/30C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,404,927
App. No.
14/561,313
Granted
Aug 2, 2016
Kind
B2
Abstract

Embodiments of the invention provide a method detecting and treating cancer, such as lung cancer. In some aspects, the method may include detecting cancer in a subject, which may comprise assessing the expression of a marker in a sample from the subject. For example, the marker may comprise c-Met and/or Fn14. In some embodiments, if the subject is diagnosed as having cancer, the method may further provide administering a therapeutically effective amount of a substance that reduces the expression level of Fn14 to the subject to reduce the invasive and migratory capabilities of the cancer.

Claims (6)

1. A method of diagnosing non-small cell lung cancer, the method comprising the steps of:

receiving a sample from a subject suspected of having non-small cell lung cancer;

detecting a level of expression of c-Met in the sample from the subject, wherein the level of expression of c-Met is determined relative to a control sample;

detecting a level of expression of Fn14 in the sample from the subject, wherein the level of expression of Fn14 is determined relative to the control sample; and

wherein the subject is diagnosed as having cancer when the levels of expression of the at least one growth factor receptor and Fn14 are both elevated compared to the control sample.

2. The method of claim 1 , further comprising treating the non-small cell lung cancer once the subject has been diagnosed, the method of treating the non-small cell lung cancer comprising administering a therapeutically effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises at least one of an inhibitor of Fn14 and c-Met.

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 23, 2015
From: TRANSLATIONAL GENOMICS RESEARCH INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037151/0886 →
CONFIRMATORY LICENSE Recorded Dec 23, 2014
From: TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034699/0441 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2014
From: WHITSETT, TIMOTHY G.; TRAN, NHAN
To: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
Reel/Frame 034512/0702 →
Continuity (2)
Provisional Application 61912067 · Dec 5, 2013
Related Publication 20150323538A1 · Nov 12, 2015